Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials.
To characterize immune cell expression among patients with Non-Muscle Invasive Bladder Cancer (NMIBC) treated with BCG. Patients with NMIBC treated with intravesical BCG (2008-2015) were identified, and a TMA was constructed using paired pre and post-BCG bladder samples. Immunohistochemistry was performed for CD8, CD4, FoxP3, PD-L1 (SP-142 and 22C3) and PD-1. A full slide review of PD-L1+ staining tumors was performed to characterize PD-L1 and CD8 co-localization. RNAseq was performed on cored tumors from available specimens. We compared immune cell populations between BCG responders and nonresponders, and between pretreatment and postreatment tumor samples. Baseline PD-L1 staining in the BCG naive population was then validated in a separate cohort. The final cohort contained 63 pretreatment NMIBC cases, including 31 BCG responders and 32 BCG non-responders. No differences in CD4, CD8, or FoxP3 expression were identified between responders and non-responders. Baseline PD-L1 expression (22C3 and SP-142) was observed in 25-28% of nonresponders and 0-4% of responders (P<0.01). PD-L1+ cells in BCG nonresponders co-localized with CD8+ T-cells. Additionally BCG therapy did not increase PD-L1 gene expression (RNAseq) or protein levels (IHC). The number of pre-treatment CD4+ T-cells was very low among PD-L1+ non-responders (12%) and high among PD-L1- non-responders (50%, p<0.01). In a separate cohort of 57 NMIBC patients undergoing BCG, baseline PD-L1 staining was similar (26%). One mechanism of BCG failure may be adaptive immune resistance. Baseline tumor PD-L1 expression predicts an unfavorable response to BCG and if validated, could be used to guide therapeutic decisions.